Arcturus Therapeutics is poised to become an industry leader in the application of RNAi technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of therapeutic modalities, Arcturus is on the forefront of research and development of nanoparticle siRNA drug delivery systems.
Arcturus Therapeutics Begins Operations in Janssen Labs
Learn about Janssen Labs — an innovative environment where biotechnology entrepreneurs are working to create the future of healthcare.Read More
Become an investor in Arcturus Therapeutics. Visit our investor relations page for more details on how you can invest in an industry leader in RNAi technologies.Read More
Arcturus Therapeutics is poised to be a leader in the area of nanoparticle therapeutics. To be successful, Arcturus will leverage the experience of its founders to rapidly file IND applications.Read More